📰 Beigene News
Page 24 - Beigene News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Beigene. Real-time updates on events, politics, business and more.
August 17, 2021
BeiGene, Ltd. (NASDAQ:BGNE; HKEX:06160) and EUSA Pharma (UK), Ltd. today announced that the China National Medical Products Administration (NMPA) has granted QARZIBA(dinutuximab beta) conditional approval
August 5, 2021
Der französische Hauptstadt-Gemeindeverband Métropole du Grand Paris gewährt Privatpersonen Zuschüsse in Höhe von bis zu 6.000 Euro für den Kauf von alternativ betriebenen Fahrzeugen (BEV, FCEV, PHEV,
May 28, 2021
Moderna enlisted Samsung Biologics to help with fill-finish of its mRNA COVID-19 vaccine. Astellas targeted $17 billion in fiscal 2025 sales in a new five-year plan. Novo Holdings co-led a $200 million financing round in a Singapore cell and gene therapy tech company. And more
January 16, 2021
Brazilian researchers first said Sinovac’s COVID-19 vaccine, CoronaVac, was 78% effective in a local phase 3 trial. But then, a few days ago, they released new data of just 50.4% efficacy. The gap was caused by the omission of “very mild” infections in the previous data. The misstep led to criticism of the trial organization, Brazil’s Butantan biomedical center, as well as suspicion about CoronaVac’s true efficacy. Turkey just authorized the shot for emergency use based on a reported...
January 15, 2021
On January 11th, Novartis signed a strategic collaboration agreement to in-license tislelizumab from BeiGene in major markets outside of China
January 13, 2021
BeiGene announces Novartis collaboration on antibody By Liu Zhihua | chinadaily.com.cn | Updated: 2021-01-13 11:13 Share CLOSE Scientists discuss use of equipment at the central chemistry lab of BeiGene in Beijing in May 2017. [Photo provided to chinadaily.com.cn] China-based biotechnology company BeiGene Ltd held a media conference in Beijing on Tuesday to announce its collaboration and license agreement with Swiss pharmaceutical compa...
January 12, 2021
BASEL (dpa-AFX) - China-based biotechnology companyBeiGene Ltd. (BGNE) said that it will collaborate with Novartis to develop, manufacture and commercialize BeiGene's cancer drug tislelizumab
January 12, 2021
Message : Required fields (Reuters) - Swiss drugmaker Novartis paid $650 million to snag an immuno-oncology drug from BeiGene Ltd, the latest Western drugmaker turning to China for must-have assets to fill holes in their cancer portfolios. Novartis Chief Executive Vas Narasimhans move, which could bring $1.55 billion in milestone payments and royalties for BeiGene, is also an about-face from comments two years ago when he raised data quality and innovation worries as barriers to Big Pharmas...
January 12, 2021
* Novartis’s China foray follows Pfizer deal in September * Swiss drugmaker playing catch-up on cancer immunotherapy * Novartis CEO was previously tepid on Chinese assets Jan 12 (Reuters) - Swiss drugmaker Novartis paid $650 million to snag an immuno-oncology drug from BeiGene Ltd , the latest Western drugmaker turning to China for must-have assets to fill holes in their cancer portfolios. Novartis Chief Executive Vas Narasimhan’s move, which could bring $1.55 billion in milestone payments ...
January 12, 2021
Here’s what we’re watching as markets kick into gear on Tuesday. — U.S. stock futures edged higher Tuesday, suggesting major indexes will resume their recent climb after a slide in technology shares weighed on markets at the start of the week. Read our full market wrap here. What’s Coming Up —Home builder KB Home will deliver its quarterly earnings report after markets close. —Live Q&A: Join WSJ chief economics correspondent Nick Timiraos for an interview with the St. Louis Fed’...